CoChat

Glutamate normalization with ECT treatment response in major depression

Open access
Zhang, J, Narr, K L, Woods, R P, Phillips, O R, Alger, J R, Espinoza, R T · 2013 · Molecular Psychiatry
Cited by 70

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Though psychotherapy, medications and brain stimulation are used to treat major depressive disorder (MDD), treatment response depends on several individualized clinical factors and frequently requires multiple treatment trials. To guide more effective personalized interventions, there is thus a need to identify biological markers to elucidate the mechanisms of response to predict treatment outcomes in MDD. Prior evidence suggests neurochemical disturbances in mood regulating networks, including the anterior cingulate cortex (ACC) and connected prefrontal and subcortical centers, contribute to MDD and play a role in treatment response1–4. To identify treatment-related changes in neurochemical markers implicated in MDD2, 4, 5, we applied single-voxel Proton Magnetic Resonance Spectroscopy (1HMRS) for cross sectional and longitudinal analysis of ACC glutamate (Glu), choline (Cho) and N-acetyl aspartate (NAA) in 10 patients with DSM-IVR diagnoses of MDD (mean age: 44.0 years, 7.93 SD; 6 females) followed prospectively during Index treatment and 10 demographically similar controls (mean age: 39.03 years, 9.55 SD; 6 females). Electroconvulsive therapy (ECT) was used as the therapeutic modality since it is a highly effective procedure for treating severe MDD that elicits rapid response in eligible individuals6. Patients were assessed at three time points: baseline, and after the 2nd and 6th ECT sessions, corresponding to ~48 hrs and 2 weeks post treatment initiation (see Supplementary Information (SI) for clinical details). The Hamilton (HAMD) and Montgomery-Asberg (MADRS) Depression Rating Scales recorded therapeutic response. Controls were assessed twice, ~2-weeks apart, to determine disease effects, normative values and to estimate the variance of serial scanning. All subjects, without neurological disorders, alcohol/substance abuse or dementia, provided UCLA Institutional Review Board-approved informed consent. High-resolution T1-weighted MPRAGE structural (FOV: 256; voxel size: 1 mm3; TR/TE: 2200/5.16 ms; flip angle: 12°) and single-voxel Point Resolved Spectroscopy (PRESS) acquisitions (TR/TE: 2000/30 ms; spectral width 2000 Hz; 1024 points) with (128 averages) and without water suppression (8 averages) were collected on a Siemens 3T Allegra system. Automatic and manual 3D shimming was applied to reduce B0 inhomogeneity for voxels (20×18×12 mm3) placed in midline anterior ACC gray matter [Fig 1A; see SI]. LCModel computed the levels of Glu, Cho and NAA relative to the unsuppressed water signal. Derived metabolites levels were corrected for voxel CSF content using corresponding tissue classified T1-weighted images7. Figure 1 A) Voxel placement and 1HMRS spectra in a single subject, B) Mean CSF-adjusted glutamate (left), NAA (middle) and choline (right) levels at each time point in patients and controls indicating significant disease effects (purple), group by time interactions ... Metabolites (with variances 0.50). For baseline comparisons, including age and gender as covariates, main effects of diagnosis were observed for Glu only, F(1,19)=8.61, p<.01 (lower in patients). General Linear Mixed Models (GLMMs) including metabolites from each time point and a subject variable to control for within-subject correlations, also showed a significant diagnosis by time interaction for Glu, F(1, 21.98)=4.94, p<.037. Glu levels increased significantly over time in patients approximating normal levels, F(2, 16.56)=4.05, p<.037, but remained stable in controls (p=.47). In patients, subsequent pairwise comparisons showed significant Glu elevations between baseline and the 6th ECT, p<.018. In the absence of overall effects of time, pairwise comparisons in patients also showed significant decreases in NAA, p<.048, and increases in Cho, p<.047 between baseline and the 6th ECT [Fig 1B]. HAMD and MADRS scores improved significantly with treatment, F(2, 16.67)=29.48 and F(2, 13.12)=19.79, both p<.0001. Variations in Glu correlated with MADRS scores across time, F(1, 15.78)=4.49, p<.05. Baseline Cho levels correlated significantly with overall change in HAMD ratings, r=.85, p<.0001; baseline Glu levels also showed a trend for predicting HAMD change, r=.59, p<.08 [Fig 1C]. MDD-related reductions in ACC glutamate normalize with ECT treatment and associate with clinically determined therapeutic response. Results are in line with prior reports indicating glutamate deficits in MDD2, 4 and extend earlier observations of increased glutamate/glutamine (Glx) in the left ACC in patients treated with ECT8, shown here to also mirror clinical response. NAA and Choline, though not discriminating diagnostic groups at baseline, also showed treatment effects in patients. Together, these neurochemical changes suggest treatment-induced neuroplasticity in the structure, density and integrity of mature neurons9 and/or may reflect changes relating to adult neurogenesis in connected hippocampal and subventricular regions10. Results also support that neurochemical signatures in the ACC may predict future therapeutic response through mechanisms potentially overlapping with other forms of treatment. Studies including additional treatment modalities, larger samples, and longer follow-ups with relapse rates may confirm these observations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2012.46

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 70

Metadata

Authors
Zhang, J., Narr, K. L., Woods, R. P., Phillips, O. R., Alger, J. R., & Espinoza, R. T.
Venue
Molecular Psychiatry
Published
2012-05-08
Volume
18
Issue
3
Pages
268-270
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2075563698
Cited by
70
References
5
FWCI
3.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.